We sought to determine whether the risks and benefits of prolonging dual-antiplatelet therapy (DAPT) beyond 1 year after drugeluting stent implantation depend on clinical presentation in a metaanalysis of randomized controlled trials.
D
ual-antiplatelet therapy (DAPT) with acetyl salicylic acid and a P2Y12 inhibitor is standard of care after drug-eluting stent (DES) placement to reduce the risk of stent thrombosis and myocardial infarction (MI). 1, 2 Current evidence suggests that a tailored approach is advisable wherein the risk of ischemic versus bleeding events is carefully balanced in individual patients to guide the optimal DAPT duration. 3 In this regard, the clinical presentation may inform DAPT duration decisions after DES placement. A recent meta-analysis limited to randomized trials comparing ≤6-month versus 1-year DAPT after DES placement reported similar rates of MI or stent thrombosis in patients with stable ischemic heart disease (SIHD) but higher rates of ischemic events with 3-month versus 1-year DAPT in patients with acute coronary syndrome (ACS). 4 However, that meta-analysis did not investigate the benefits of prolonging DAPT beyond 1 year in relation to clinical presentation. Addressing this issue, a post hoc analysis from the DAPT trial (Dual Antiplatelet Therapy) found a significant interaction between DAPT duration and clinical presentation for the risk of major adverse cardiovascular and cerebrovascular events. Specifically, continued DAPT treatment compared with acetyl salicylic acid monotherapy between 1 and 2.5 years significantly reduced the risk of major adverse cardiovascular and cerebrovascular events after stenting in patients with ACS but not in patients with SIHD. 5 In addition, prolonged DAPT increased the risk of bleeding in both groups. In addition, in the PRODIGY trial (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia), there was no significant difference in ischemic end points between shorter versus longer DAPT irrespective of clinical presentation, but there was a significant increase in bleeding with longer DAPT, which was of greater magnitude in patients with SIHD compared with those with ACS. 6 Thus, the net benefit of continuing thienopyridine beyond 1 year in patients with SIHD after DES implantation remains to be determined. For this reason, we performed an aggregate pairwise meta-analysis of trials that compared ≤1-versus >1-year DAPT after DES implantation, stratifying patients according to clinical presentation.
METHODS

Study Design and Selection
The authors declare that all supporting data are available within the article (and its Data Supplement). For the present meta-analysis, randomized controlled trials (RCTs) comparing ≤1-versus >1-year DAPT were considered. Relevant RCTs were searched through MEDLINE, the Cochrane database, the EMBASE database, www.tctmd.com, www.clinicaltrials. gov, www.clinicaltrialresults.org, www.cardiosource.com, and abstracts and presentations from major cardiovascular meetings, using the key words randomized clinical trial, drug-eluting stent, dual-antiplatelet therapy, clopidogrel, aspirin, and thienopyridine. Two investigators (T.P. and A.G.B.) independently reviewed the titles, abstracts, and studies to determine whether they met the inclusion criteria. Risk of bias of RCTs was assessed using the Cochrane tool. 7 The protocol of the meta-analysis was not reported in any website. T.P. had full access to all the data in the study and takes responsibility for its integrity and the data analysis
End Points and Definitions
The primary efficacy end point of the study was MI, whereas the primary safety end point was major bleeding, as defined in the component trials of the meta-analysis. We also considered the net clinical benefit defined as the composite of MI or major bleeding. Other secondary end points were all-cause death (and subclassified as cardiac or noncardiac), stroke, definite or probable stent thrombosis, and a various combination of these end points. Results were stratified by clinical presentation as defined in the component trials of the meta-analysis, and interaction analyses were performed to analyze differences in treatment effect across patient strata. We performed analyses by intention to treat (ITT), as reported in each original trial. In addition, to minimize the dilution of treatment effect by events occurring in the early period when both groups were treated with DAPT, landmark analyses were performed from the time of DAPT discontinuation in the shorter DAPT treatment group. Thus, in trials randomizing patients at the time of or 1 month after percutaneous coronary intervention, but before the time of DAPT allocation, patients with ischemic or bleeding events occurring before the landmark time point were excluded, comprising a modified ITT population. The present review was performed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis statement.
7
WHAT IS KNOWN
• Compared with shorter dual-antiplatelet therapy (DAPT), prolonged DAPT reduces the risk of ischemic events but increases the risk of bleeding and bleeding-related deaths. It is unclear whether the net benefit of prolonging DAPT beyond 1 year is influenced by clinical presentation.
WHAT THE STUDY ADDS
• In this aggregate data-based meta-analysis including 6 randomized controlled trials and 21 457 patients, prolonging DAPT beyond 1 year significantly reduced the risk of myocardial infarction and increased the risk of bleeding compared with ≤1-year DAPT, irrespective of clinical presentation. However, the magnitude of treatment effect depended on clinical presentation such that a significant net benefit with prolonged DAPT was apparent in patients with acute coronary syndrome but not in patients with stable coronary artery disease.
Statistical Analysis
Continuous variables are displayed as means and SD, whereas categorical variables are displayed as count and percentages. Hazard ratios (HRs) and 95% CIs were used as the summary statistic. Estimates of risk were extracted from the main publications of RCTs, obtained from principal investigators, or calculated as described previously. 2 The pooled hazard ratio (HR) was calculated by using both fixed-effect (inverse-variance weighted) and random-effect (DerSimonian and Laird) models. Extent of small study effects/publication bias was assessed by visual inspection of funnel plots and the Egger test. Pairwise inconsistency was assessed with the I2 statistic. P <0.05 was considered statistically significant. Statistical analyses were performed using Stata 12 SE (StataCorp, College Station, TX).
RESULTS
The flowchart of the study is reported in Figure I in the Data Supplement. Aggregate data were obtained for 6 studies whose reference is reported in the Data Supplement. The presenting clinical syndrome was SIHD in 14 132 patients and ACS in 7325 patients. Among those with SIHD, 7036 were treated with ≤1-year DAPT and 7096 with >1-year DAPT, whereas among patients with ACS, 3654 were treated with ≤1-year DAPT and 3671 with >1-year DAPT. The major features of the included trials are shown in Table I in the Data Supplement, and the clinical characteristics of patients stratified by presentation type are reported in Tables  II and III in the Data Supplement. The inclusion and exclusion criteria of patients randomized in the trials included in the meta-analysis are shown in Table IV in the Data Supplement, the clinical characteristics of the overall patient population from the individual randomized trials are shown in Table V in the Data Supplement, the definitions of the clinical end points from each trial appear in Table VI in the Data Supplement, the risk of bias of the component trials of the meta-analysis using the Cochrane tool are reported in Table VII in the Data Supplement, and the quality assessment of outcomes using the Grading of Recommendations Assessment, Development and Evaluation tool in Table VIII in the Data Supplement.
Primary Efficacy and Safety End Point in the ITT Population
After a median follow-up of 19.5 months, 281 MIs occurred in the 14 132 patients with SIHD compared with 204 MIs in the 7325 patients with ACS (1.9% for SIHD versus 2.8% for ACS; P<0.001). As shown in Figure 1 , ≤1-year DAPT was associated with increased rates of MI compared with >1-year DAPT (HR, 1.63; 95% CI, 1.37-1.95; P<0.0001), with no apparent interaction between treatment effect and clinical presentation (P interaction =0.27). Specifically, among patients with SIHD, there were 168 MIs with shorter DAPT versus 112 with longer DAPT (HR, 1.50; 95% CI, 1.19-1.90), whereas in patients with ACS, there were 124 MIs with shorter DAPT versus 70 with longer DAPT (HR, 1.84; 95% CI, 1.40-2.42). Thus, the numbers needed to treat (95% CI) to prevent 1 MI in patients with SIHD and ACS were 124 (79-286) and 59 (41-105), respectively.
No significant difference in the rates of major bleeding was apparent between patients with SIHD compared with those with ACS. Specifically, there were 108 episodes of major bleeding in patients with SIHD versus 56 in patients with ACS (0.8% in each group; P=0.99). As shown in Figure 1 , ≤1-year DAPT was associated with significantly lower rates of major bleeding compared with >1-year DAPT (HR, 0.64; 95% CI, 0.42-0.99; P=0.01). Among patients with SIHD, there were 39 episodes of major bleeding with shorter DAPT versus 69 with longer DAPT (HR, 0.49; 95% CI, 0.28-0.87), whereas in patients with ACS, there were 27 episodes of major bleeding with shorter DAPT versus 29 with longer DAPT (HR, 0.94; 95% CI, 0.48-1.81; P interaction =0.14). The numbers needed to harm (95% CI) were 240 (142-761) in SIHD and 1959 (95% CI not measurable) in ACS.
As shown in the visual overview, (Estimates of risk in the intention-to-treat population for the composite of myocardial infarction [MI] or major bleeding between ≤1-year DAPT and >1-year DAPT. Subtotal refers to the estimates of risk in each cohort of patients.) a significant interaction was apparent between DAPT duration and clinical presentation for the net clinical benefit end point (P interaction =0.04), which favored >1-year DAPT in patients with ACS (HR of shorter versus longer DAPT, 1.59; 95% CI, 1.24-2.02; P<0.0001) but not in patients with SIHD (HR, 0.86; 95% CI, 0.56-1.34; P=0.17). The numbers needed to treat (95% CI) to achieve net benefit in patients with SIHD and ACS were 267 (95% CI not measurable) and 61 (40-124), respectively.
Other Clinical Outcomes in the ITT Population
Other composite outcomes in patients treated with ≤1-versus >1-year DAPT are shown in Figures 2 and 3. Patients treated with ≤1-year DAPT had significantly lower rates of noncardiac mortality compared with those treated with >1-year DAPT (HR, 0.71; 95% CI, 0.52-0.96; P=0.03). Among patients with SIHD, there were 34 noncardiac deaths with shorter DAPT versus 60 with longer DAPT (HR, 0.58; 95% CI, 0.38-0.86), whereas in patients with ACS, there were 33 noncardiac deaths with shorter DAPT versus 35 with longer DAPT (HR, 0.94; 95% CI, 0.59-1.52; P interaction =0.12). There were no significant differences in the rates of cardiac mortality or all-cause mortality according to DAPT duration in all patients or in either patient cohort. Shorter DAPT was associated with higher rates of definite or probable stent thrombosis compared with longer DAPT (HR, 1.95; 95% CI, 1.23-3.08; P<0.0001), with no significant interaction between treatment effect and clinical presentation.
Clinical Outcomes in the Modified ITT Population
The modified ITT population consisted of 21 352 patients. There were 14 109 patients with SIHD (7025 and 7084 of whom were randomized to ≤1-and >1-year DAPT, respectively) and 7243 patients with ACS (3613 and 3630 of whom were randomized to ≤1-and >1-year DAPT, respectively). Results in the modified ITT population were similar to the ITT population. In particular, as shown in Figure II 
DISCUSSION
In the present study, we investigated the risk-benefit profile of >1-year DAPT compared with ≤1-year DAPT after DES implantation in relation to clinical presentation using an aggregate data-based meta-analysis of 6 RCTs that enrolled 21 457 patients. The principal findings are that shorter DAPT was associated with increased rates of MI and reduced rates of major bleeding compared with longer DAPT, with no significant interactions between treatment effect and clinical presentation. Moreover, the absolute magnitude and relative treatment effects of >1-year DAPT compared with ≤1-year DAPT in reducing MI and increasing major bleeding depended on clinical presentation, such that a significant interaction was apparent between DAPT duration and clinical presentation for the composite net clinical benefit end point of MI or major bleeding, favoring longer DAPT in patients with ACS but not in those with SIHD.
We performed the present aggregate data-based pairwise meta-analysis including 6 randomized trials comparing ≤1-versus >1-year DAPT in 21 457 patients, 14 132 and 7325 of whom had SIHD and ACS, respectively. Prolonging DAPT beyond 1 year substantially reduced the risk of MI and of stent thrombosis but increased the risk of major bleeding, in both patients with SIHD and ACS. However, the net risk-benefit profile of prolonged DAPT as measured by the difference in MI or major bleeding differed depending on clinical presentation. Specifically, longer DAPT reduced the risk of MI compared with shorter DAPT to a greater degree in patients with ACS than in those with SIHD, with numbers needed to treat of 59 and 124, respectively. In contrast, the increased major bleeding risk of prolonged DAPT was less in patients with ACS compared with those presenting with SIHD, with numbers needed to harm of 1959 and 240, respectively. As a consequence, a significant interaction was present between DAPT duration and the composite of MI or major bleeding, such that a net clinical benefit with >1-year DAPT was apparent in patients with ACS but not in those with SIHD. The benefits of prolonged DAPT also included a reduction in stent thrombosis with no apparent interaction between treatment effect and clinical presentation, although significant heterogeneity in the effect estimate was present across trials in patients with SIHD. Although all-cause and cardiac mortality were not significantly related to DAPT duration, noncardiac mortality was greater in patients treated with longer DAPT compared with shorter DAPT, with no apparent interaction between treatment effect and clinical presentation. This effect was mainly driven by the DAPT trial 1 but was also consistent across the other trials included in the meta-analysis (I 2 =22%). The definitions of MI or major bleeding used in the RCTs included in the meta-analyses should be considered to place these findings in perspective. Specifically, the majority of trials used a sensitive definition for spontaneous MI, which included a rise in troponin levels above the upper normal limit, whereas major bleeding in the different trials consisted of Thrombolysis in Myocardial Infarction major bleeding, The Global Use of Strategies to Open Occluded Arteries severe bleeding, or Bleeding Academic Research Consortium type 3 or 5 bleeding, which have consistently been associated with mortality. 8 The sensitive definition of MI, which may include events with uncertain prognostic relevance, may account for the fact that longer DAPT decreased MI without concomitantly reducing cardiac mortality either in patients with SIHD or ACS. In contrast, ≤1-year DAPT was associated not only with a reduction of major bleeding but also with a significant reduction of noncardiac death compared with >1-year DAPT in all patients but especially in those with SIHD. Although in this study we could not investigate the mechanistic underpinnings of this association, a recent meta-analysis has reported a direct association between prolonged DAPT, bleeding, and mortality. 8 Specifically, compared with longer DAPT, shorter DAPT was associated with significantly lower rates of bleeding-related death, whereas no significant difference was apparent between the 2 treatment arms in deaths not related to bleeding.
Finally, whether prolonged DAPT is associated with an increase in all-cause mortality in patients undergoing DES implantation remains controversial. Higher rates of all-cause mortality with longer versus shorter DAPT after DES implantation were previously reported from a pairwise and Bayesian network meta-analysis of 10 trials with 31 666 patients. 2 Since then, 5 more trials that enrolled an additional 8753 patients have been published comparing different durations of DAPT after DES placement. [9] [10] [11] [12] [13] In a meta-analysis from these 15 trials and 40 419 patients, shorter DAPT was associated with lower rates of all-cause mortality compared with longer DAPT (HR, 0.85; 95% CI, 0.73-0.99; P=0.037) with no significant heterogeneity across studies ( Figure  VI in the Data Supplement). Some earlier meta-analyses have refuted this association. 14, 15 However, those reports included a variety of conditions for which different DAPT durations have been studied, including for secondary prevention, patients with prior MI, atrial fibrillation, peripheral arterial disease, as well as DES or bare metal stent implantation. Perhaps reflecting this diversity, the effect estimate of mortality in those metaanalyses was associated with moderate heterogeneity ranging from 27% to 40%, suggesting the presence of effect modifiers across the included study populations. 14, 15 The neutral effect of long-term DAPT on allcause mortality after DES use even in patients with ACS from the present report may reflect a greater impact on mortality of major bleeding compared with spontaneous MI, as defined in the studies from the present meta-analysis. More research is required in this regard to characterize the attributable risk of different types of adverse ischemic and bleeding events after percutaneous coronary intervention.
Limitations
First, among the 6 trials included in the meta-analysis, 3 of them randomized patients at the time of percutaneous coronary intervention or 1 month after the procedure and not at the time of DAPT allocation. Events thus occurring before DAPT discontinuation in the aspirin monotherapy arm would serve only to confound any differences between the treatment arms. To address this limitation, we performed a landmark analysis of events in the period between DAPT discontinuation and the end of follow-up, excluding events occurring before the landmark time point of DAPT discontinuation. In this modified ITT cohort, similar results were apparent as in the ITT population. Second, a significant proportion of implanted DES were first generation devices, which are no longer used in clinical practice. The risk-benefit profile for prolonged DAPT may be less favorable with secondgeneration DES use. 16 Third, the duration of follow-up and definitions of some clinical end points slightly differed across trials, potentially introducing effect modifiers. In particular, different definitions of major bleeding across trials could influence the relative difference in the bleeding risk in patients with ACS versus SIHD, potentially biasing the interaction effect between DAPT duration and clinical presentation. Fourth, several trials included in the meta-analysis were open label, potentially introducing bias. Fifth, most patients included in the present meta-analysis were treated with clopidogrel as adjunctive therapy to aspirin. It remains undetermined whether our results would have been different with the new and more potent antiplatelet drugs prasugrel and ticagrelor. Sixth, patients were stratified according to clinical presentation as defined in the component trials of the meta-analysis. The different definitions of ACS across trials may be responsible of treatment effect heterogeneity apparent for some end points. Seventh, because not all prior studies reported all composite events of interest (eg, MI or major bleeding), we assumed these events were independent, which may not be true in all cases. However, both events contribute to the burden of patient outcomes. Finally, cardiac biomarkers were not available in patients with ACS, and, therefore, we could not investigate their impact on outcomes.
In conclusion, although >1-year DAPT reduces the risk of MI compared with ≤1-year DAPT after DES implantation, it also increases the risk of major bleeding. An overall net clinical benefit for prolonged DAPT was observed in patients with ACS but not for those with SIHD. A tailored decision-making process is advisable after DES implantation wherein the clinical presentation is factored in with other variables associated with the individual risk of ischemic versus bleeding events to decide on the optimal duration of DAPT after DES implantation.
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